Skip to main content
Publications
Shih JY, Lin SH, Nagar SP , Davis KL , Jimenez MI , Kahangire DA, Servidio L, Ho L, Veluswamy R. Treatment patterns in resectable early-stage NSCLC in Taiwan: subgroup analysis of a global real-world study . Poster presented at the 2022 ESMO Asia Congress; December 2, 2022. Singapore, Republic of Singapor.
Fernandez M, Bell TJ, Khan S , Tumminello B, Bektas M , Heyes CE , Oton AB. Burden of illness of desmoid tumors . Poster presented at the 2022 CTOS Annual Meeting; November 16, 2022. Vancouver, Canada. Previously presented at the 2022 Desmond Tumor Research Foundation (DTRF) Annual Meeting.
Bonastre J, Negrier S, Colrat F, Chamielec C, Teitsson S, Knight C, Ni L , Chevalier J, Gaudin AF, Roupret M, Branchoux S. Impact of method for modelling distant recurrence (DR) on cost-effectiveness (CE) of nivolumab (NIVO) as an adjuvant treatment of muscle-invasive urothelial carcinoma (MIUC) patients with high risk of recurrence in France . Presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria.
Veluswamy R, Ahn MJ, Nagar S , Affi R, Agulnik J, Shih JY, Hochmair MJ, Tufman A, Debieuvre D, Jimenez MI , Davis K , Kahangire DA, Servidio L, di Perna C, Lin SH. Surgical resection, treatment patterns and outcomes in patients (pts) with early-stage non-small cell lung cancer (NSCLC): interim analysis of a global real-world study . Poster presented at the 2022 International Thoracic Surgical Oncology Summit; September 30, 2022. New York, NY.
Spira A, Zhou X , Liao L, Yu E, Chen L, Lau A, Wang Y, Gnanasakthy A , Radford J, Hamadani M. Health-related quality of life and tolerability in patients with/without skin toxicity during loncastuximab tesirine treatment in a phase 2 clinical trial (LOTIS-2) . Poster presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022); September 28, 2022. Houston, TX.
Wainberg ZA, Enzinger PC, Qin S, Yamaguchi K, Gnanasakthy A , Taylor K, Jamotte A, Majer I, Kang YK. Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6 . Poster presented at the 2022 ESMO Annual Conference; September 9, 2022. Paris, France.
Stattin P, Westerberg M, Franck Lissbrant I, Hjalm-Eriksson M, Kjellman A, Ullen A, Vassilev Z, Sandstrom P, Weinrib R , Martinez D , Garcia de Albeniz Martinez X . Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden . Clin Genitourin Cancer. 2022 Sep 9;S1558-7673(22):00194-X. doi: 10.1016/j.clgc.2022.09.002
Salles G, Schuster SJ, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith S, Davis KL , Ubieto A, Nagar S , Zhang AJ, Bollu V, Jousseaume E, Ramos R, Wang Y, Link BK. A retrospective cohort study of treatment outcomes of adult patients with relapsed or Refractory Follicular Lymphoma (ReCORD-FL) . Hemasphere. 2022 Jun 21;6(7):e745. doi: 10.1097/HS9.0000000000000745
Diez-Campelo M, Yucel A, Goyal R , Parikh R , Dhuliawala S, Jimenez M , Sluga-O'Callaghan M , Hughes C, Tang D, Germing U. Systemic therapy utilization and hematologic outcomes in lower-risk myelodysplastic syndromes (LR-MDS): findings from a real-world medical record review study in the US, UK, and Europe (EU) . Poster presented at the 2022 European Hematology Association Hybrid Congress; June 10, 2022. Vienna, Austria.
Spira A, Liao L, Zhou X , Gnanasakthy A , Chen L, Ungar D, Yu E, Kilavuz T, Radford J, Hamadani M. Health-related quality of life and tolerability of loncastuximab tesirine in high-risk patients with relapsed/refractory diffuse large B-cell lymphoma treated in a phase 2 clinical trial (LOTIS 2) . Poster presented at the 2022 EHA Congress; June 9, 2022. Vienna, Austria.
Lin SH, Ahn M, Nagar S , Affi R, Agulnik J, Shih J, Hochmair MJ, Tufman A, Debieuvre D, Jimenez MI , Davis K , Kahangire DA, Servidio L, Veluswamy R. Treatment patterns and outcomes in resectable early stage NSCLC: interim analysis of a global real-world study . Poster presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3, 2022. Chicago, IL.
Motzer R, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Bennett L , Wang J , Pan JJ, Saretsky TL, Perini RF, He CS, Mody K, Cella D. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study . Lancet Oncol. 2022 Jun;23(6):768-80. doi: 10.1016/S1470-2045(22)00212-1
Kummar S, Shen L, Martinus van Tilburg C, Tan DSW, Doz F, McDermott RS, Zwaan CM, Keating KN, Chirila C , Norenberg R, Fellous MM, Brega N, Xu R, Laetsch TW, Drilon AE, Hong DS. Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials . Poster presented at the 2022 ASCO Annual Meeting; June 3, 2022. Chicago, IL. [abstract] Am J Clin Oncol. 2022 Jun; 40(16_suppl):6563. doi: 10.1200/JCO.2022.40.16_suppl.6563
Bhatia S, Nghiem P, Veeranki SP, Vanegas A , Lachance K, Tachiki L, Chiu K, Boller E, Bharmal M. Real-world clinical outcomes among patients with advanced Merkel cell carcinoma treated with avelumab in academic medical centers in the United States . Presented at the 2022 2nd International Symposium on Merkel Cell Carcinoma; April 25, 2022. Seattle, WA. Previously presented at the SITC 2021 36th Anniversary Annual Meeting.
Spira A, Liao L, Zhou X , Sherif B , Chen L, Ungar D, Yu E, Radford J, Hamadani M. Health-related quality of life, symptoms, and tolerability of Loncastuximab Tesirine in older versus younger patients with relapsed/refractory diffuse large b-cell lymphoma treated in a phase 2 clinical trial (LOTIS-2) . Poster presented at the National Comprehensive Cancer Network (NCCN) 2022 Virtual Annual Conference; March 31, 2022.
Spira A, Zhou X , Chen L, Gnanasakthy A , Wang L, Ungar D, Curiel R, Liao L, Radford J, Kahl B. Health-related quality of life, symptoms, and tolerability of Loncastuximab Tesirine in patients with relapsed or refractory diffuse large b-cell lymphoma . Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):158-68. doi: 10.1016/j.clml.2021.09.001
Auclair D, Mansfield C , Fiala MA, Chari A, Cole CE, Kaufman JL, Orloff GJ, Siegel DS, Zonder JA, Mange B, Yesil J, Dalal M, Mikhael JR. Preferences and priorities for relapsed multiple myeloma treatments among patients and caregivers in the United States . Patient Prefer Adherence. 2022 Mar 1;2022(16):573-85. doi: 10.2147/PPA.S345906
Law EH, Galve-Calvo E, Wockel A, Parikh R , Kurosky SK, Derrien Ansquer V , Frugier G , Davis KL , Esterberg E , Oikonomidou O. European treatment patterns and outcomes associated with first-line CDK4/6 inhibition and hormonal therapies assessed in a real-world non-interventional study (EUCHARIS) . Poster presented at the 2021 San Antonio Breast Cancer Symposium (SABCS); December 7, 2021. San Antonio, TX. [abstract] Cancer Res. 2022 Feb 15; 82(4_Suppl):OT2-19-04. doi: 10.1158/1538-7445.SABCS21-OT2-19-04